ReviewVirchows Archiv : an international journal of pathology2023
Follicular lymphoma and marginal zone lymphoma: how many diseases?
Review in Virchows Archiv : an international journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study.British journal of haematology · 2025Trial
- MNDA-positive Follicular Lymphoma is a heterogeneous disease: a case series study of 19 patients.Virchows Archiv : an international journal of pathology · 2026Article
- Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma.Molecular cancer therapeutics · 2026Review
- Article
- Ocular adnexal lymphomas: A comprehensive review with emphasis on histopathologic and magnetic resonance imaging appearance.Histology and histopathology · 2026Review
- Ocular adnexa follicular lymphoma: clinicopathological study of 23 patients.Virchows Archiv : an international journal of pathology · 2026Article
- Prognostic significance of Ki-67 in grade 3A follicular lymphoma and development of a novel PFS nomogram.Annals of hematology · 2026Article
- Zanubrutinib for the treatment of cutaneous relapse of systemic marginal zone lymphoma: A case report.JAAD case reports · 2026Article
- Wandering Lymphoma: A Case of Wandering Spleen Secondary to Splenic Marginal Zone Lymphoma.Case reports in hematology · 2026Article
- Real-world safety profile of mosunetuzumab: a pharmacovigilance study based on the food and drug administration adverse event reporting system.Frontiers in pharmacology · 2026Article
- Marginal zone lymphoma presenting with chylous ascites: A rare clinical manifestation and successful treatment with orelabrutinib-rituximab.SAGE open medical case reports · 2026Article
- Analysis of the efficacy and prognostic factors of gemcitabine combined with oxaliplatin in non-Hodgkin lymphoma.Oncology letters · 2025Article
- From CT to Microscopy: Radiological-Histopathological Correlation for Understanding Abdominal Lymphomas.Cancers · 2025Article
- Exploring the boundaries between neoplastic and reactive lymphoproliferations: lymphoid neoplasms with indolent behavior and clonal lymphoproliferations-a report of the 2024 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2025Review
- Article
- Article
- Localized light chain amyloidosis of the stomach that regressed after eradication of Helicobacter pylori over 15 years of follow-up: a case report and new hypothesis.Clinical journal of gastroenterology · 2025Article
- Article
- Exploring causal relationship between 41 inflammatory cytokines and marginal zone lymphoma: A bidirectional Mendelian randomization study.Open medicine (Warsaw, Poland) · 2025Article
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent mature B-cell neoplasms with variable clinical presentation and distinct histopathologic features. Recent advances in the biology and molecular characteristics of these lymphomas have further expanded our understanding of the heterogeneous nature of these lymphomas, with increasing recognition of specific disease entities within the broader categories of FL and MZL. Here, we discuss the conclusions of the 2022 International Consensus Classification of Mature Lymphoid Neoplasms (2022 ICC) dealing with FL, and review differences with the proposed WHO 5th Edition classification. We review issues related to grading and alternative forms of FL especially those lacking the genetic hallmark of FL, the t(14;18) chromosomal alteration. Among them, t(14;18)-negative CD23
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.